BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Caris Life Sciences Target Now(TM) Targets Cancer Treatment Selection


11/30/2011 8:32:43 AM

IRVING, TX--(Marketwire - November 29, 2011) -

As research into cancer care advances, physicians can now take better aim in the care of their cancer patients, using evidence-based molecular profiling to help determine which cancer therapies are more likely to be effective and which therapies are likely to be ineffective.

A new evidence-based molecular profiling system -- called Caris Target Now™ -- is bringing about dramatic changes in the personalization of cancer care.

No two cancers are alike and cancer treatment plans shouldn't be either. Treatment that works well for one person may be ineffective for another, because each patient's cancer has different genetics. Caris Target Now™ makes it possible to detect those differences, match a tumor's genetics with specific drugs more likely to be effective, and flag therapies with less chance of working.

Personalized cancer treatment like this can increase quality of life, uncover treatments previously not considered, and cut healthcare costs.

One multicenter study conducted by Caris Life Sciences, and published in the Journal of Clinical Oncology, showed that Caris Target Now™ molecular profiling increased progression free survival from various cancers, including late-stage cancer, in 27 percent of 86 patients studied who had their therapy selected this way, versus the previous therapy on which they had progressed.

Sandeep K. Reddy, MD, oncology expert and clinical associate professor of medicine, Geffen/UCLA School of Medicine, discusses Caris Target Now™, and Sandra Fehrman, a cancer patient, explains how this technology helped to extend and enhance her life, in this moving video.

For more information about the role of molecular profiling in cancer therapy selection, patients can visit www.mycancer.com and healthcare professionals may be interested in www.caristargetnow.com.


Contact:
Lisa Fullam
Lisa4LFA@aol.com
480.585.6950

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES